NCT01019863Unknown2 期
Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2008年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Response rate to RGDOx in patients with relapsing or refractory NHL
研究概览
简要总结
Evaluation of the efficacy, tolerance, quality of life and cost effectiveness of the association of Oxaliplatin, Gemcitabine, Rituximab and Dexamethasone for treatment of patients with refractory or relapsing non-Hodgkin lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients 18 years or above at the time of inclusion.
- •Documented CD20+ NHL, refractory or relapsing after first line chemotherapy.
- •No contraindication to Oxaliplatin, Gemcitabine, Dexamethasone or Rituximab.
排除标准
- •Other types of non-Hodgkin lymphoma
- •Pregnancy and lactation.
- •Patient unable to give written informed consent.
- •Contra-indication ou intolerance to any of the components of the RGDOx chemotherapy.
研究组 & 干预措施
Oxaliplatin
Experimental
oxaliplatin associated with Rituxan,Gemcitabine, and Dexamethasone in patients with refractory or relapsed Non hodgkinien lymphoma
干预措施: oxaliplatin (Drug)
结局指标
主要结局
Response rate to RGDOx in patients with relapsing or refractory NHL
时间窗: Within 3 months after chemotherapy (6-8 cycles)
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic CrcColorectal CancerNCT00755118University Hospital of Crete24
Unknown
2 期
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic MetastasisHepatocellular CarcinomaNCT04170179Sun Yat-sen University25
已完成
2 期
Gemox as First and Second Line Therapy in Unknown Primary CancerUnknown Primary NeoplasmsNCT00353145M.D. Anderson Cancer Center29
已完成
1 期
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasChildhood Burkitt LymphomaChildhood Central Nervous System Germ Cell TumorChildhood Diffuse Large Cell LymphomaChildhood Grade III Lymphomatoid GranulomatosisChildhood Immunoblastic Large Cell LymphomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Liver CancerRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway GliomaRecurrent Colon CancerRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent MelanomaRecurrent Nasopharyngeal CancerRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent Wilms Tumor and Other Childhood Kidney TumorsRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol SpecificNCT00101270National Cancer Institute (NCI)24
已完成
1 期
Combination Chemotherapy in Treating Young Patients With Advanced Solid TumorsChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Embryonal TumorChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorRecurrent Childhood Brain Stem GliomaRecurrent Childhood Central Nervous System Embryonal TumorUnspecified Childhood Solid Tumor, Protocol SpecificNCT00281944National Cancer Institute (NCI)42